Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18412868 | 0.85 | LMNA (0.44) | ALDH1A1LMNANPC1TSHRHPGD | |
| SCHEMBL1717058 | 0.85 | TSHR (0.58) | ALDH1A1LMNANPC1TSHRHPGD | |
| SCHEMBL28448359 | 0.84 | ALDH1A1 (0.48) | ALDH1A1LMNANPC1TSHRHPGD | |
| SCHEMBL28036519 | 0.83 | MAPK14 (0.46) | ALDH1A1LMNANPC1GABRPGABRD | |
| SCHEMBL7811465 | 0.82 | MAPK14 (0.43) | — | |
| SCHEMBL31352358 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNANPC1TSHRGABRP | |
| SCHEMBL31352127 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNANPC1TSHRGABRP | |
| SCHEMBL4599422 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNANPC1TSHRGABRP | |
| SCHEMBL173434 | 0.80 | NPC1 (0.68) | ALDH1A1LMNANPC1TSHRHPGD | |
| SCHEMBL3580133 | 0.79 | LMNA (0.54) | ALDH1A1LMNANPC1TSHRNR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115976586-A | Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating | 昆山一鼎工业科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| CN-115976586-B | Forward and reverse pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating | 昆山一鼎工业科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025002177-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 长春金赛药业有限责任公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| CN-115976586-A | Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating | 昆山一鼎工业科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110066282-B | Pyrazolopyrimidinone compound and preparation method and application thereof | 南开大学 | 2020-07-10 | — | — | CN | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| EP-3233863-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2017-10-25 | — | — | EP | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| WO-2016097869-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| CN-102617580-B | Vasopressin v1a antagonists | VANTIA LTD | 2015-03-04 | — | — | CN | disclosed |
| CN-102617580-A | Vasopressin V1a Antagonists | FERRING BV | 2012-08-01 | — | — | CN | disclosed |
| WO-2010118367-A2 | ANTIVIRAL PYRIMIDINES | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| CN-101563347-A | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2009-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | ALDH1A1 467/4885LMNA 3874/4885NPC1 1059/4885 |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | NR4A3, NR4A1, NR3C1 | ALDH1A1 4205/4885LMNA 3013/4885NPC1 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.